Cour Pharmaceuticals$30M funding was raised by, a Chicago-based, clinical-stage biotechnology company that develops novel immune-modifying nanoparticles.
Alpha Wave Ventures led the round. As part of the financing, Chris Dimitropoulos, Managing Director, Biotechnology at Alpha Wave Global, will join COUR’s Board of Directors.
The company plans to use the funds for its CNP platform technology expansion and to advance its two human proof of concept studies in Primary Biliary Cholangitis, Peanut allergy, and development programs in Myasthenia Gravis as well as Type 1 Diabetes.
Cour Pharmaceuticals, headed by John J. Puisis as CEO, is creating first-in-class therapies to reprogram the immune system and achieve antigen-specific tolerance to immune-mediated diseases. Its immune-modifying platform nanoparticles target the root cause immune disease. This is in contrast to other approaches that only address symptoms.
The underlying technology was acquired from Northwestern University and draws from more than 30 years of research in immune tolerance.
FinSMEs
07/09/2022